Physician profile
Cherry Chau
NPI 1609496462
$2,639.47
in general payments reported to CMS, 2019-2025
16 companies · $1,141 in 2025
The $1,141 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $172 · 2024: $1,327 · 2025: $1,141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,639.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,639.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $632.42 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $468.28 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Abbott Laboratories | $387.49 | 2023-2025 | Freestyle Libre 3, Proclaim |
| Exact Sciences Corporation | $251.23 | 2024-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $232.92 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $166.97 | 2023-2025 | Repatha, Otezla, Otezla |
| Phathom Pharmaceuticals, INC. | $110.08 | 2024-2025 | Voquezna |
| Dexcom, INC. | $89.76 | 2024-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.30 | 2024-2025 | Jardiance |
| Sumitomo Pharma America, INC. | $61.21 | 2024-2025 | Gemtesa |
| Xeris Pharmaceuticals, INC. | $38.46 | 2025 | Gvoke Hypopen |
| Glaxosmithkline, LLC. | $38.39 | 2023-2025 | Shingrix, Arexvy, Fluarix Quadrivalent |
| Azurity Pharmaceuticals, INC. | $36.79 | 2024 | Horizant, Edarbi |
| Kowa Pharmaceuticals America, INC. | $14.35 | 2025 | Zoryve |
| Currax Pharmaceuticals LLC | $14.21 | 2025 | Contrave |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.61 | 2025 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cherry Chau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.